Compare Nutrien Ltd (NTR) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutrien Ltd vs Organon & Co. Common Stock — how do they compare? Nutrien Ltd trades at $69.87 (market cap $33.13B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Nutrien Ltd is far larger — about 9.2× Organon & Co. Common Stock's market cap, and Nutrien Ltd pays the higher dividend (3.16%). Which is the better fit depends on your goals — on Pluang, investors hold Nutrien Ltd for 60 Days and Organon & Co. Common Stock for 0 Days on average.
| NTR | OGN | |
|---|---|---|
Market Cap | $33.13B | $3.62B |
Volume | 2,165,412 | 2,892,999 |
Sector | Basic Materials | Health |
52-Week High | $83.94 | $13.81 |
52-Week Low | $53.64 | $5.70 |
Typical Hold Time | 60 Days | 0 Days |
Enterprise Value | $44.94B | $11.04B |
Dividend Yield | 3.16% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTR trades at $69.87, up 2.75% today, with mixed technical signals showing bearish momentum but oversold conditions on some indicators. The company demonstrates solid fundamentals with $26.89B revenue, 8.44% net margin, and attractive valuation ratios including P/E of 14.11. Recent earnings show volatility with Q2 2026 missing estimates but Q1 beating expectations. Analyst sentiment remains positive with 60.61% buy ratings and $77.29 consensus target.
NTR presents a compelling value opportunity with reasonable valuations and strong cash flow generation, though facing headwinds from fertilizer industry challenges and competitive pressures. The stock's current discount to analyst targets suggests potential upside, but investors should monitor execution on cost discipline and volume recovery amid fluctuating commodity prices and geopolitical factors affecting fertilizer markets.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
